Crossject : Fund raising to prepare for hoped-for Zepizure approval in Q1 2025
>Capital increase of € 8m with a discount of 10% - Crossject on Tuesday announced the launch of a capital increase for € 8m. This deal is secured through its long-standing shareholder Gemme Venture. The latter has committed to subscribing to at least € 1.96m worth (24.5% of the capital increase) and will guarantee a total amount of € 6m, or 75% of the fund raising.The subscription price is € 1.848 which equates to a discount of 10% to the last share price (4.3m n...Crossject SA is a France-based company that designs and develops medical injection systems. The Company specializes in needle-free, pre-filled, single-use injection systems for intradermal, subcutaneous and intramuscular applications for pharmaceutical companies. Is also has a pipeline and three drugs in the preclinical or clinical phase of research. The Company's products, which are based on well-known injectable drugs (chemicals and biologics), are designed to enhance patients' safety, compliance and comfort. Crossject's first ZENEO SUPERGENERIC product is expected to reach the market in the year 2015. The Company has industrial partnerships with Hirtenberger and Recipharm.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.